Skip to main navigation Skip to search Skip to main content

Danspot: A Multicenter Stepped-Wedge Cluster-Randomized Trial of the Reclassification of Acute Myocardial Infarction: Rationale and Study Design

  • Nina Strandkjær*
  • , Nicoline Jørgensen
  • , Rasmus Bo Hasselbalch
  • , Jonas Kristensen
  • , Marie Sophie Sander Knudsen
  • , Thilde Olivia Kock
  • , Theis Lange
  • , Matias Greve Lindholm
  • , Niels Eske Bruun
  • , Lene Holmvang
  • , Christian Juhl Terkelsen
  • , Claus Kjær Pedersen
  • , Martin Kirk Christensen
  • , Jens Flensted Lassen
  • , Linda Hilsted
  • , Søren Ladefoged
  • , Mads Nybo
  • , Mustafa Vakur Bor
  • , Morten Dahl
  • , Annebirthe Bo Hansen
  • Pia Rørbæk Kamstrup, Henning Bundgaard, Christian Torp-Pedersen, Kasper Karmark Iversen
*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

BACKGROUND: Cardiac troponins are the preferred biomarkers for the diagnosis of acute myocardial infarction. Although sex-specific 99th percentile thresholds of troponins are recommended in international guidelines, the clinical effect of their use is poorly investigated. The DANSPOT Study (The Danish Study of Sex- and Population-Specific 99th percentile upper reference limits of Troponin) aims to evaluate the clinical effect of a prospective implementation of population- and sex-specific diagnostic thresholds of troponins into clinical practice.

METHODS: This study is a nationwide, multicenter, stepped-wedge cluster-randomized trial of the implementation of population- and sex-specific thresholds of troponins in 22 of 23 clinical centers in Denmark. We established sex-specific thresholds for 5 different troponin assays based on troponin levels in a healthy Danish reference population. Centers will sequentially cross over from current uniform manufacturer-derived thresholds to the new population- and sex-specific thresholds. The primary cohort is defined as patients with symptoms suggestive of acute coronary syndrome having at least 1 troponin measurement performed within 24 hours of arrival with a peak troponin value between the current uniform threshold and the new sex-specific female and male thresholds. The study will compare the occurrence of the primary outcome, defined as a composite of nonfatal myocardial infarction, unplanned revascularization, and all-cause mortality within 1 year, separately for men and women before and after the implementation of the new sex-specific thresholds.

CONCLUSIONS: The DANSPOT Study is expected to show the clinical effects on diagnostics, treatment, and clinical outcomes in patients with myocardial infarction of implementing sex-specific diagnostic thresholds for troponin based on a national Danish reference population.

REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05336435.

Original languageEnglish
Article numbere033493
Number of pages11
JournalJournal of the American Heart Association
Volume13
Issue number9
Early online date19 Apr 2024
DOIs
Publication statusPublished - 7 May 2024

Keywords

  • Biomarkers/blood
  • Denmark/epidemiology
  • Female
  • Humans
  • Male
  • Myocardial Infarction/blood
  • Predictive Value of Tests
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Sex Factors
  • Troponin/blood

Fingerprint

Explore the research areas of 'Danspot: A Multicenter Stepped-Wedge Cluster-Randomized Trial of the Reclassification of Acute Myocardial Infarction: Rationale and Study Design'.

Cite this